Abstract
Introduction Dimethyl-fumarate is a recently approved drug for relapsing-remitting Multiple Sclerosis in Italy. Clinical case A 55-year-old woman started therapy with dimethyl-fumarate on June 2014; it was well-tolerated aside from moderate flushing. Starting September 2014 she noticed a progressive hair loss, that neither the dermatological examination nor clinical and medical history nor blood investigations could explain. The hair loss slowed down after two months and was followed by a hair growth back. Discussion Transient hair loss is not a reported side effect of dimethyl-fumarate therapy but by excluding any known cause we attributed it to the beginning of the new therapy.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 68-69 |
Numero di pagine | 2 |
Rivista | Multiple Sclerosis and Related Disorders |
Volume | 7 |
DOI | |
Stato di pubblicazione | Pubblicato - 2016 |
Keywords
- Alopecia
- Dimethyl Fumarate
- Dimethyl-fumarate
- Disease modifying therapies
- Female
- Hair loss
- Humans
- Immunosuppressive Agents
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting
- Multiple sclerosis
- Neurology
- Neurology (clinical)
- Side effect